Posted by Michael Wonder on 02 Nov 2022
US FDA approves Vemlidy (tenofovir alafenamide) for treatment of chronic hepatitis B virus infection in paediatric patients
2 November 2022 - Approval expands on previous FDA approval of Vemlidy in adults living with this chronic liver disease.
Gilead Sciences today announced that the US FDA has approved the supplemental new drug application for Vemlidy (tenofovir alafenamide) 25 mg tablets as a once daily treatment for chronic hepatitis B virus infection in paediatric patients 12 years of age and older with compensated liver disease.
